Asset Details
Do you wish to reserve the book?
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Do you wish to request the book?
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
2013
Overview
Increasing animal genetic, post-mortem and pharmacological evidence supports a role for the cerebral type 1 cannabinoid (CB1) receptor in the pathogenesis of schizophrenia (SCZ) and/or neural circuit dysfunctions responsible for its symptomatology. Moreover, since important interspecies differences are present in CB1 receptor expression, in vivo human data are of direct interest. We investigated an in vivo CB1 receptor expression in SCZ patients compared to healthy controls (CON), and in relation with psychopathological symptom severity using positron emission tomography (PET) and the selective high-affinity radioligand [18F]MK-9470.
A total of sixty-seven patients with SCZ, with (SCZ-T, n=51) and without (SCZ-F, n=16) antipsychotic treatment, and 12 age and gender-matched CON were investigated with [18F]MK-9470 PET. Parametric modified standardized uptake value (mSUV) images, reflecting CB1 receptor binding, were compared and related to psychopathological symptoms. Compared to CON, there was a significant increase of CB1 receptor binding in SCZ patients in the nucleus accumbens, insula, cingulate cortex, inferior frontal cortex, parietal and mediotemporal lobe. Furthermore, in the SCZ-F group only, CB1 receptor binding was negatively correlated to negative symptoms and to depression scores, especially in the nucleus accumbens. Present findings strongly support that CB1 receptor binding is altered in the mesocorticolimbic circuitry of both SCZ-T and SCZ-F patients, especially in the nucleus accumbens. In SCZ-F patients, it is associated with negative symptoms and depression scores.
•This is the first CB1R PET study investigating more than 60 SCZ patients.•This is the first CB1R PET study including patients with and without antipsychotics.•CB1R is increased in patients with SCZ both with and without antipsychotics.•CB1R binding is increased in selected mesocorticolimbic regions of SCZ patients.•Increased striatal CB1R binding is related to negative symptoms.
Publisher
Elsevier Inc,Elsevier
Subject
/ Adult and adolescent clinical studies
/ Antipsychotic Agents - therapeutic use
/ Biological and medical sciences
/ Corpus Striatum - diagnostic imaging
/ Corpus Striatum - drug effects
/ Corpus Striatum - metabolism
/ Female
/ Humans
/ Male
/ Patients
/ PET
/ Pharmacology. Drug treatments
/ Psychodysleptics: hallucinogen
/ Psychology. Psychoanalysis. Psychiatry
/ Pyridines - pharmacokinetics
/ Radiopharmaceuticals - pharmacokinetics
/ Receptor, Cannabinoid, CB1 - metabolism
/ Schizophrenia - diagnostic imaging
